Structure

InChI Key GLMUAFMGXXHGLU-VQAITOIOSA-N
Smile CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl
InChI
InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32);1H/t9-,11-,17-,23-;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H28ClN3O7
Molecular Weight 493.94
AlogP 0.19
Hydrogen Bond Acceptor 9.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 3.0
Polar Surface Area 164.63
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 33.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial 70S ribosome inhibitor KEGG PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Periodontitis 4 D010518 ClinicalTrials
Acne Vulgaris 4 D000152 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
13.76
Nervous system disorders
10.11
General disorders and administration site conditions
9.56
Immune system disorders
9.06
Musculoskeletal and connective tissue disorders
7.51
Vascular disorders
6.59
Gastrointestinal disorders
5.34
Cardiac disorders
4.91
Injury, poisoning and procedural complications
4.08
Hepatobiliary disorders
3.73
Respiratory, thoracic and mediastinal disorders
3.72
Investigations
3.08
Blood and lymphatic system disorders
2.78
Eye disorders
2.68
Psychiatric disorders
2.58
Infections and infestations
2.34

Cross References

Resources Reference
ChEBI 50697
ChEMBL CHEMBL1200881
EPA CompTox DTXSID8044545
FDA SRS 0020414E5U
KEGG C07225
SureChEMBL SCHEMBL2537
ZINC ZINC14879992